Biomarkers, Omics and Artificial Intelligence for Early Detection of Pancreatic Cancer.

Seminars in Cancer Biology, Journal Year: 2025, Volume and Issue: 111, P. 76 - 88

Published: Feb. 20, 2025

Language: Английский

---

Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy

Cancer Letters, Journal Year: 2024, Volume and Issue: unknown, P. 217350 - 217350

Published: Nov. 1, 2024

Pancreatic cancer remains one of the most challenging malignancies to treat due its late-stage diagnosis, aggressive progression, and high resistance existing therapies. This review examines latest advancements in early detection, therapeutic strategies, with a focus on emerging biomarkers, tumor microenvironment (TME) modulation, integration artificial intelligence (AI) data analysis. We highlight promising including microRNAs (miRNAs) circulating DNA (ctDNA), that offer enhanced sensitivity specificity for early-stage diagnosis when combined multi-omics panels. A detailed analysis TME reveals how components such as cancer-associated fibroblasts (CAFs), immune cells, extracellular matrix (ECM) contribute therapy by creating immunosuppressive barriers. also discuss interventions target these components, aiming improve drug delivery overcome evasion. Furthermore, AI-driven analyses are explored their potential interpret complex data, enabling personalized treatment strategies real-time monitoring response. conclude identifying key areas future research, clinical validation regulatory frameworks AI applications, equitable access innovative comprehensive approach underscores need integrated, outcomes pancreatic cancer.

Language: Английский

---

Hereditary Pancreatic Cancer: Advances in Genetic Testing, Early Detection Strategies, and Personalized Management

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(2), P. 367 - 367

Published: Jan. 9, 2025

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with five-year survival rate of approximately 13% for advanced stages. While the majority PDAC cases are sporadic, significant subset attributable to hereditary and familial predispositions, accounting 25% cases. This article synthesizes recent advancements in understanding, detection, management pancreatic cancer (PC). Results: Our review highlights critical role genetic testing (GT) identifying high-risk individuals (HRIs), germline pathogenic variants (PVs) found up 20% Since implementation next-generation sequencing (NGS) panels 2014, detection capabilities have been significantly enhanced. HRIs can be included screening programs that facilitate early PDAC. Early strategies, including use microribonucleic acid (miRNAs) signatures novel imaging techniques like hyperpolarized 13C-magnetic resonance spectroscopy (MRS) shown promising results. The identification or mutations homologous recombination (HR) genes plays predictive response various treatments, prolonging patient survival. Discussion: Universal PDAC, as recommended by National Comprehensive Cancer Network (NCCN), now standard practice, facilitating at-risk enabling targeted surveillance intervention. Multidisciplinary management, integrating counseling, imaging, gastrointestinal services, essential optimizing outcomes. Conclusions: Advances biomarker research transforming landscape PC management. personalized treatment strategies pivotal improving rates. Ongoing multi-institutional efforts crucial validating biomarkers developing preventive measures, ultimately aiming reduce burden this aggressive cancer.

Language: Английский

---

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian

Cancers, Journal Year: 2024, Volume and Issue: 16(13), P. 2329 - 2329

Published: June 26, 2024

Pancreatic cancer, with its alarming rising incidence, is predicted to become the second deadliest type of solid tumor by 2040, highlighting urgent need for improved diagnostic and treatment strategies. Despite medical advancements, five-year survival rate pancreatic cancer remains about 14%, dropping further when metastasized. This review explores promise biomarkers early detection, personalized treatment, disease monitoring. Molecular classification into subtypes based on genetic mutations, gene expression, protein markers guides decisions, potentially improving outcomes. A plethora clinical trials investigating different strategies are currently ongoing. Targeted therapies, among which those against CLAUDIN 18.2 inhibitors Claudin 18.1, have shown promise. Next-generation sequencing (NGS) has emerged as a powerful tool comprehensive genomic analysis tumors, revealing unique alterations that drive progression. allows oncologists tailor therapies target specific molecular abnormalities. However, challenges remain, including limited awareness uptake biomarker-guided therapies. Continued research mechanisms essential developing more effective treatments patient rates.

Language: Английский

---

A novel electrochemical biosensor based on TiO2 nanotube array films for highly sensitive detection of exosomes

Talanta, Journal Year: 2025, Volume and Issue: 286, P. 127545 - 127545

Published: Jan. 6, 2025

Language: Английский

---

MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potential

Frontiers in Cell and Developmental Biology, Journal Year: 2025, Volume and Issue: 12

Published: Jan. 15, 2025

Pancreatic cancer (PC) remains one of the most lethal malignancies, primarily due to its intrinsic resistance conventional therapies. MicroRNAs (miRNAs), key regulators gene expression, have been identified as crucial modulators drug mechanisms in this type. This review synthesizes recent advancements our understanding how miRNAs influence treatment efficacy PC. We thoroughly summarized and discussed complex role miRNA mediating PC treatment. By highlighting specific that are implicated pathways, we provide insights into their functional interactions with molecular targets. also explore potential miRNA-based strategies novel therapeutic approaches diagnostic tools overcome improve patient outcomes. Despite promising developments, challenges such specificity, stability, effective delivery therapeutics remain. aims offer a critical perspective on current research propose future directions for leveraging interventions fight against

Language: Английский

---

Leveraging Epigenetic Alterations in Pancreatic Ductal Adenocarcinoma for Clinical Applications

Seminars in Cancer Biology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Diagnostic and Prognostic Accuracy of MiRNAs in Pancreatic Cancer: A Systematic Review and Meta‐Analysis

Journal of Cellular and Molecular Medicine, Journal Year: 2025, Volume and Issue: 29(2)

Published: Jan. 1, 2025

ABSTRACT Pancreatic cancer (PC) remains a significant contributor to global mortality, with limited effective diagnostic and prognostic tools. MicroRNAs (miRNAs) have emerged as promising biomarkers for PC diagnosis prognosis. A comprehensive literature search was conducted in PubMed, Web of Science, Scopus. Studies reporting sensitivity, specificity or area under the curve (AUC) miRNAs diagnosis, well hazard ratios (HRs) survival evaluations, were included. Data extraction quality assessment followed PRISMA guidelines. Meta‐analyses using appropriate statistical methods. The protocol is registered PROSPERO. Diagnostic analysis included 290 revealing an overall AUC 0.8226 diagnosis. Subgroup analyses showed varying accuracies, blood tissue specimens yielding higher values. Promising values above 0.8 miR‐320, miR‐1290, miR‐93, miR‐25, miR‐451, miR‐20, miR‐21, miR‐223 miR‐122. Prognostic encompassed 46 studies, indicating associations between miRNA expression (OS) progression‐free (PFS). combined HR studies OS HRs than one 1.7613 (95% CI: 1.5394–2.0152, p < 0.0001; I 2 = 81.7%). Notable significance miR‐10, miR‐21 miR‐221. less had pooled 0.6805 0.5862–0.7901, 65.4%). MiRNAs hold promise PC. Blood offer superior accuracy, several show potential predicting patient outcomes.

Language: Английский

---

Role of noncoding RNA and protein interaction in pancreatic cancer

Chinese Medical Journal, Journal Year: 2025, Volume and Issue: unknown

Published: April 10, 2025

Abstract Noncoding RNAs (ncRNAs) are a class of RNA molecules with little or no protein-coding potential. Emerging evidence indicates that ncRNAs frequently dysregulated and play pivotal roles in the pathogenesis pancreatic cancer. Their aberrant expression can arise from chromosomal abnormalities, transcriptional control, epigenetic modifications. function as protein scaffolds molecular decoys to modulate interactions between proteins other biomolecules, thereby regulating gene contributing cancer progression. In this review, we summarize mechanisms underlying ncRNA dysregulation cancer, emphasize biological significance ncRNA–protein interactions, highlight their clinical relevance. A deeper understanding is essential elucidate advance translational research

Language: Английский

---

Tumor-Educated Platelet, a Potential Liquid Biopsy Biosource in Pancreatic Cancer: A Review

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: unknown, P. 155986 - 155986

Published: April 1, 2025

Language: Английский

---